Brain-targeted delivery of Tempol-loaded nanoparticles for neurological disorders

References

• Aliautdin RN, Kreuter J, Kharkevich DA. (2003). [Drug delivery to the brain with nanoparticles.] Eksp Klin Farmakol, 66, 65–68.
   PubMedGoogle Scholar
• Ambani LM, Van Woert MH, Murphy S. (1975). Brain peroxidase and catalase in Parkinson disease. Arch Neurol, 32, 114–118.
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Li S, Li Y, Alakhov VY, Kabanov AV. (2004). Effect of pluronic P85 on ATPase activity of drug efflux transporters. Pharm Res, 21, 2226–2233.
   PubMed Web of Science ®Google Scholar
• Bickel U, Yoshikawa T, Landaw EM, Faull KF, Pardridge WM. (1993). Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery. Proc Natl Acad Sci USA, 90, 2618–2622.
   PubMed Web of Science ®Google Scholar
• Carroll RT, Galatsis P, Borosky S, et al. (2000). 4-Hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (Tempol) inhibits peroxynitrite-mediated phenol nitration. Chem Res Toxicol, 13, 294–300.
   PubMed Web of Science ®Google Scholar
• Chaturvedi RK, Beal MF. (2008). Mitochondrial approaches for neuroprotection. Ann N Y Acad Sci, 1147, 395–412.
   PubMed Web of Science ®Google Scholar
• Ebadi M, Sharma SK, Ghafourifar P, Brown-Borg H, El Refaey H. (2005). Peroxynitrite in the pathogenesis of Parkinson’s disease and the neuroprotective role of metallothioneins. Meth Enzymol, 396, 276–298.
   PubMed Web of Science ®Google Scholar
• Gu F, Zhang L, Teply BA, et al. (2008). Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci USA, 105, 2586–2591.
   PubMed Web of Science ®Google Scholar
• Gupta Y, Jain A, Jain SK. (2007). Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J Pharm Pharmacol, 59, 935–940.
   PubMed Web of Science ®Google Scholar
• Hatakeyama H, Akita H, Maruyama K, Suhara T, Harashima H. (2004). Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo. Int J Pharm, 281, 25–33.
   PubMed Web of Science ®Google Scholar
• Huwyler J, Wu D, Pardridge WM. (1996). Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA, 93, 14164–14169.
   PubMed Web of Science ®Google Scholar
• Illum L, Jones PD, Baldwin RW, Davis SS. (1984). Tissue distribution of poly(hexyl 2-cyanoacrylate) nanoparticles coated with monoclonal antibodies in mice bearing human tumor xenografts. J Pharmacol Exp Ther, 230, 733–736.
   PubMed Web of Science ®Google Scholar
• Kreuter J. (2001). Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev, 47, 65–81.
   PubMed Web of Science ®Google Scholar
• Liang Q, Smith AD, Pan S, et al. (2005). Neuroprotective effects of TEMPOL in central and peripheral nervous system models of Parkinson’s disease. Biochem Pharmacol, 70, 1371–1381.
   PubMed Web of Science ®Google Scholar
• Liu M, Chen JH, Dong FR, Liu Y. (2008). [Optimized preparation of ginkgolides A and B long-circulating solid lipid nanoparticles by central composite design and response surface method.] Nan Fang Yi Ke Da Xue Xue Bao, 28, 700–703.
   PubMedGoogle Scholar
• Magenheim B, Levy MY, Benita S. (1993). A new in vitro technique for evaluation of drug release profile from colloidal carriers-ultrafiltration technique at low pressure. Int J Pharmaceut, 94, 115–123.
   Web of Science ®Google Scholar
• Maruyama K, Takizawa T, Yuda T, Kennel SJ, Huang L, Iwatsuru M. (1995). Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Biochim Biophys Acta, 1234, 74–80.
   PubMed Web of Science ®Google Scholar
• Michaelis K, Hoffmann MM, Dreis S, et al. (2006). Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther, 317, 1246–1253.
   PubMed Web of Science ®Google Scholar
• Moreira PI, Honda K, Liu Q, et al. (2005). Oxidative stress: the old enemy in Alzheimer’s disease pathophysiology. Curr Alzheimer Res, 2, 403–408.
   PubMedGoogle Scholar
• Mu L, Feng SS. (2003). PLGA/TPGS nanoparticles for controlled release of paclitaxel: effects of the emulsifier and drug loading ratio. Pharm Res, 20, 1864–1872.
   PubMed Web of Science ®Google Scholar
• Olivier JC, Huertas R, Lee HJ, Calon F, Pardridge WM. (2002). Synthesis of pegylated immunonanoparticles. Pharm Res, 19, 1137–1143.
   PubMed Web of Science ®Google Scholar
• Pappert EJ, Tangney CC, Goetz CG, et al. (1996). Alpha-tocopherol in the ventricular cerebrospinal fluid of Parkinson’s disease patients: dose-response study and correlations with plasma levels. Neurology, 47, 1037–1042.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. (2004). Intravenous, non-viral RNAi gene therapy of brain cancer. Expert Opin Biol Ther, 4, 1103–1113.
   PubMed Web of Science ®Google Scholar
• Rao US, Scarborough GA. (1994). Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of the human P-glycoprotein. Mol Pharmacol, 45, 773–776.
   PubMed Web of Science ®Google Scholar
• Sahoo SK, Labhasetwar V. (2005). Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm, 2, 373–383.
   PubMed Web of Science ®Google Scholar
• Shao J, Li X, Lu X, et al. (2009). Enhanced growth inhibition effect of resveratrol incorporated into biodegradable nanoparticles against glioma cells is mediated by the induction of intracellular reactive oxygen species levels. Colloids Surf B Biointerfaces, 72, 40–47.
   PubMed Web of Science ®Google Scholar
• Temsamani J, Rousselle C, Rees AR, Scherrmann JM. (2001). Vector-mediated drug delivery to the brain. Expert Opin Biol Ther, 1, 773–782.
   PubMed Web of Science ®Google Scholar
• The Parkinson Study Group. (1993). The effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med, 328, 176–183.
   PubMed Web of Science ®Google Scholar
• Ulbrich K, Hekmatara T, Herbert E, Kreuter J. (2009). Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm, 71, 251–256.
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Pardridge WM. (1992). Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor. J Pharmacol Exp Ther, 263, 897–903.
   PubMed Web of Science ®Google Scholar